AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
Lantern Pharma (NASDAQ: LTRN), a biotech company leveraging its RADR(R) AI platform to accelerate precision oncology drug development, has engaged IBN to lead its corporate communications strategy. With clinical programs targeting lung, brain, breast, and blood cancers—including three AI-guided candidates and a CNS-focused subsidiary—Lantern is advancing multiple FDA-designated therapies in active trials. The partnership with IBN aims to expand investor awareness as Lantern pursues key milestones across its data-driven, biomarker-informed pipeline. To view the full press release, visit https://ibn.fm/Yflb4 About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery…